VistaGen Therapeutics, Inc. (Vistagen), fomerly Excaliber Enterprises, Ltd., is a biotechnology company. The Company’s integrated stem cell biology platform, Human Clinical Trials in a Test Tube, is designed to provide an early indication, or prediction, of the cardiac toxicity of drug candidates before they are ever tested in humans. The Company’s products include CardioSafe 3D, LiverSafe 3D and AV-101. CardioSafe 3D is a three-dimensional biological assay (screening) system that uses human heart cells to screen for cardiac toxicity. On May 11, 2011, Vistagen Therapeutics, Inc., a California corporation, merged with Excaliber Merger Subsidiary, Inc., which is a subsidiary of the Company. Cato Holding Company acquired its Vistagen shares and warrants in a number of transactions between August 30, 2001 and May 10, 2011.